44 3.2.2 Rationale for dose ........................................................................................... 44 3.2.3 Rationale for GM- CSF ( Molgramostim) adjuvant .......................................... 45 3.2.4 Rationale for dose regimen ............................................................................. 45 3.2.5 Use of Gemcitabine as adjuvant chemotherapy .............................................. 47 3.3 Selection of trial populat ion ......................................................................................